company background image
GTHR logo

GeneThera OTCPK:GTHR Stock Report

Last Price

US$0.000001

Market Cap

US$35.0

7D

0%

1Y

n/a

Updated

28 Mar, 2024

Data

Company Financials

GTHR Stock Overview

GeneThera, Inc., a biotechnology company, develops molecular assays and therapeutics for the detection and treatment of zoonotic diseases.

GTHR fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health0/6
Dividends0/6

GeneThera, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for GeneThera
Historical stock prices
Current Share PriceUS$0.000001
52 Week HighUS$0.011
52 Week LowUS$0.000001
Beta0.46
1 Month Change0%
3 Month Changen/a
1 Year Changen/a
3 Year Change-100.00%
5 Year Change-99.99%
Change since IPO-100.00%

Recent News & Updates

Recent updates

Shareholder Returns

GTHRUS BiotechsUS Market
7D0%0.9%0.4%
1Yn/a10.3%28.8%

Return vs Industry: Insufficient data to determine how GTHR performed against the US Biotechs industry.

Return vs Market: Insufficient data to determine how GTHR performed against the US Market.

Price Volatility

Is GTHR's price volatile compared to industry and market?
GTHR volatility
GTHR Average Weekly Movementn/a
Biotechs Industry Average Movement11.6%
Market Average Movement6.0%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.0%

Stable Share Price: GTHR has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine GTHR's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
n/a2Tony Milicihttps://www.genethera.net

GeneThera, Inc., a biotechnology company, develops molecular assays and therapeutics for the detection and treatment of zoonotic diseases. It offers treatments for zoonotic diseases, such as COVID -19 disease; paratuberculosis (Johne’s disease) that is in Stage III clinical phase; mad cow and chronic wasting diseases; and E.coli and salmonella infections, as well as develops vaccine for mycobacterium avium sub paratuberculosis bacteria. The company’s Molecular Robotic/AI Platform and Therapeutic strategy is designed to prevent the spread of disease from animals and allow to better control of zoonotic infectious agents.

GeneThera, Inc. Fundamentals Summary

How do GeneThera's earnings and revenue compare to its market cap?
GTHR fundamental statistics
Market capUS$35.00
Earnings (TTM)-US$681.26k
Revenue (TTM)n/a

0.0x

P/S Ratio

0.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
GTHR income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$681.26k
Earnings-US$681.26k

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.019
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio-9.5%

How did GTHR perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.